These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 26341082)

  • 1. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
    Bender RJ; Mac Gabhann F
    BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
    Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
    Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.
    Osada R; Horiuchi A; Kikuchi N; Ohira S; Ota M; Katsuyama Y; Konishi I
    Hum Pathol; 2006 Nov; 37(11):1414-25. PubMed ID: 17010410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.
    Gaur P; Bielenberg DR; Samuel S; Bose D; Zhou Y; Gray MJ; Dallas NA; Fan F; Xia L; Lu J; Ellis LM
    Clin Cancer Res; 2009 Nov; 15(22):6763-70. PubMed ID: 19887479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
    Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
    Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer.
    Bender RJ; Mac Gabhann F
    PLoS One; 2013; 8(5):e61788. PubMed ID: 23667446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
    Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
    Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
    Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I
    Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaphorin-4D (Sema-4D), the Plexin-B1 ligand, is involved in mouse ovary follicular development.
    Regev A; Goldman S; Shalev E
    Reprod Biol Endocrinol; 2007 Mar; 5():12. PubMed ID: 17376242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
    Krishnan B; Torti FM; Gallagher PE; Tallant EA
    Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4.
    Zhou H; Yang YH; Basile JR
    Angiogenesis; 2014 Jan; 17(1):261-74. PubMed ID: 24114199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.
    Dhanabal M; Wu F; Alvarez E; McQueeney KD; Jeffers M; MacDougall J; Boldog FL; Hackett C; Shenoy S; Khramtsov N; Weiner J; Lichenstein HS; LaRochelle WJ
    Cancer Biol Ther; 2005 Jun; 4(6):659-68. PubMed ID: 15917651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.
    Mu HQ; He YH; Wang SB; Yang S; Wang YJ; Nan CJ; Bao YF; Xie QP; Chen YH
    Clin Transl Oncol; 2020 Jan; 22(1):111-121. PubMed ID: 31667686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.